These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1325463)

  • 1. A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours.
    Verweij J; Planting A; van der Burg M; Stoter G
    J Cancer Res Clin Oncol; 1992; 118(8):606-8. PubMed ID: 1325463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer.
    Planting AS; Stoter G; Verweij J
    Eur J Cancer; 1993; 29A(4):518-9. PubMed ID: 8435202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine.
    Pronk LC; Planting AS; Oosterom R; Drogendijk TE; Stoter G; Verweij J
    Eur J Cancer; 1994; 30A(7):1019-22. PubMed ID: 7946566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of oral miltefosine in patients with squamous cell head and neck cancer.
    Verweij J; Gandia D; Planting AS; Stoter G; Armand JP
    Eur J Cancer; 1993; 29A(5):778-9. PubMed ID: 8471342
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours.
    Crul M; Rosing H; de Klerk GJ; Dubbelman R; Traiser M; Reichert S; Knebel NG; Schellens JH; Beijnen JH; ten Bokkel Huinink WW
    Eur J Cancer; 2002 Aug; 38(12):1615-21. PubMed ID: 12142051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of cutaneous metastases of a squamous cell carcinoma of the leg with topical miltefosine].
    Mahieu-Renard L; Richard MA; Dales JP; Buscaylet S; Lagrassa S; Grob JJ
    Ann Dermatol Venereol; 2005 Apr; 132(4):346-8. PubMed ID: 15886562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
    Baselga J; Rischin D; Ranson M; Calvert H; Raymond E; Kieback DG; Kaye SB; Gianni L; Harris A; Bjork T; Averbuch SD; Feyereislova A; Swaisland H; Rojo F; Albanell J
    J Clin Oncol; 2002 Nov; 20(21):4292-302. PubMed ID: 12409327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer.
    Koukourakis MI; Koukouraki S; Giatromanolaki A; Archimandritis SC; Skarlatos J; Beroukas K; Bizakis JG; Retalis G; Karkavitsas N; Helidonis ES
    J Clin Oncol; 1999 Nov; 17(11):3512-21. PubMed ID: 10550149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study.
    Verweij J; Krzemieniecki K; Kok T; Poveda A; van Pottelsberghe C; van Glabbeke M; Mouridsen H
    Eur J Cancer; 1993; 29A(2):208-9. PubMed ID: 8422284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.
    Gerrits CJ; Burris H; Schellens JH; Planting AS; van den Burg ME; Rodriguez GI; van Beurden V; Loos WJ; Hudson I; Fields S; Verweij J; von Hoff DD
    Eur J Cancer; 1998 Jun; 34(7):1030-5. PubMed ID: 9849451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
    Juric D; Dienstmann R; Cervantes A; Hidalgo M; Messersmith W; Blumenschein GR; Tabernero J; Roda D; Calles A; Jimeno A; Wang X; Bohórquez SS; Leddy C; Littman C; Kapp AV; Shames DS; Penuel E; Amler LC; Pirzkall A; Baselga J
    Clin Cancer Res; 2015 Jun; 21(11):2462-70. PubMed ID: 26034219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of s-1 plus cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer.
    Fujii M; Tomita K; Nishijima W; Tsukuda M; Hasegawa Y; Ishitoya J; Yamane H; Homma A; Tomita T
    Jpn J Clin Oncol; 2010 Mar; 40(3):214-21. PubMed ID: 19934112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
    Scott AM; Wiseman G; Welt S; Adjei A; Lee FT; Hopkins W; Divgi CR; Hanson LH; Mitchell P; Gansen DN; Larson SM; Ingle JN; Hoffman EW; Tanswell P; Ritter G; Cohen LS; Bette P; Arvay L; Amelsberg A; Vlock D; Rettig WJ; Old LJ
    Clin Cancer Res; 2003 May; 9(5):1639-47. PubMed ID: 12738716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours.
    Vink SR; Schellens JH; Beijnen JH; Sindermann H; Engel J; Dubbelman R; Moppi G; Hillebrand MJ; Bartelink H; Verheij M
    Radiother Oncol; 2006 Aug; 80(2):207-13. PubMed ID: 16914220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
    Caponigro F; Avallone A; McLeod H; Cartenì G; De Vita F; Casaretti R; Morsman J; Blackie R; Budillon A; De Lucia L; Gravina A; Catalano G; Comella P; Comella G
    Clin Cancer Res; 1999 Dec; 5(12):3948-55. PubMed ID: 10632324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers.
    Dowell JE; Sinard R; Yardley DA; Aviles V; Machtay M; Weber RS; Weinstein GS; Chalian AA; Carbone DP; Rosenthal DI
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):97-101. PubMed ID: 10210547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
    Von Pawel J
    Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
    Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
    Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
    J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.
    de Jonge M; de Weger VA; Dickson MA; Langenberg M; Le Cesne A; Wagner AJ; Hsu K; Zheng W; Macé S; Tuffal G; Thomas K; Schellens JH
    Eur J Cancer; 2017 May; 76():144-151. PubMed ID: 28324749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.